PLSec：一种用于 HCC 风险的新型液体生物标志物。
PLSec: A novel, liquid biomarker for HCC risk.
机构信息
Massachusetts General Hospital Division of Hematology-Oncology, Harvard Medical School, Boston, MA 02114, USA.
Massachusetts General Hospital Division of Gastroenterology, Harvard Medical School, Boston, MA 02114, USA.
出版信息
Med. 2021 Jul 9;2(7):788-790. doi: 10.1016/j.medj.2021.06.004.
PMID:35590215
Abstract
Cirrhosis confers a variable risk of developing hepatocellular carcinoma (HCC), but the risk varies significantly depending upon ill-defined factors. In this issue of Med, Fujiwara et al. use hepatic gene signatures and computational analysis to develop a streamlined, robust blood-based predictor of HCC risk in this population.
摘要
肝硬化使肝细胞癌 (HCC) 的发病风险具有变异性，但风险取决于多种尚未明确的因素，其变化幅度较大。在本期 Med 杂志上，Fujiwara 等人利用肝脏基因特征和计算分析，为该人群开发了一种简化、稳健的基于血液的 HCC 风险预测因子。
相似文献
1
PLSec: A novel, liquid biomarker for HCC risk.PLSec：一种用于 HCC 风险的新型液体生物标志物。
Med. 2021 Jul 9;2(7):788-790. doi: 10.1016/j.medj.2021.06.004.
2
Fibro markers for prediction of hepatocellular carcinoma in Egyptian patients with chronic liver disease.纤维标志物在预测埃及慢性肝病患者肝细胞癌中的应用。
J Med Virol. 2017 Jun;89(6):1062-1068. doi: 10.1002/jmv.24720. Epub 2016 Dec 9.
3
Computer-aided assessment of hepatic contour abnormalities as an imaging biomarker for the prediction of hepatocellular carcinoma development in patients with chronic hepatitis C.计算机辅助评估肝脏轮廓异常作为预测慢性丙型肝炎患者肝细胞癌发生的影像学生物标志物
Eur J Radiol. 2015 May;84(5):811-5. doi: 10.1016/j.ejrad.2015.01.009. Epub 2015 Jan 22.
4
Platelets' RNA as biomarker trove for differentiation of early-stage hepatocellular carcinoma from underlying cirrhotic nodules.血小板 RNA 作为生物标志物宝库，可用于区分早期肝细胞癌与潜在的肝硬化结节。
PLoS One. 2021 Sep 1;16(9):e0256739. doi: 10.1371/journal.pone.0256739. eCollection 2021.
5
LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort.基于 LC-MS 的血清代谢组学鉴定埃及队列中肝细胞癌的生物标志物。
J Proteome Res. 2012 Dec 7;11(12):5914-23. doi: 10.1021/pr300673x. Epub 2012 Nov 1.
6
NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis.基于 NMR 和 LC/MS 的代谢组学分析鉴定血清生物标志物区分肝癌与肝硬化
Int J Cancer. 2014 Aug 1;135(3):658-68. doi: 10.1002/ijc.28706. Epub 2014 Jan 17.
7
Biomarkers for the early diagnosis of bacterial infection and the surveillance of hepatocellular carcinoma in cirrhosis.用于细菌感染早期诊断及肝硬化患者肝细胞癌监测的生物标志物。
Biomark Med. 2015;9(12):1343-51. doi: 10.2217/bmm.15.100. Epub 2015 Nov 18.
8
Novel changes in glycosylation of serum Apo-J in patients with hepatocellular carcinoma.肝癌患者血清 Apo-J 糖基化的新变化。
Cancer Epidemiol Biomarkers Prev. 2011 Jun;20(6):1222-9. doi: 10.1158/1055-9965.EPI-10-1047. Epub 2011 Apr 5.
9
MR imaging in cirrhosis and hepatocellular carcinoma.肝硬化和肝细胞癌的磁共振成像
Magn Reson Imaging Clin N Am. 2014 Aug;22(3):315-35. doi: 10.1016/j.mric.2014.04.006.
10
引用本文的文献
1
Exosomes carrying immune checkpoints, a promising therapeutic approach in cancer treatment.携带免疫检查点的外泌体：癌症治疗中一种有前途的治疗方法。
Med Oncol. 2022 Sep 7;39(12):183. doi: 10.1007/s12032-022-01781-1.
Zotero 插件